Skip to main content
Equibles

Glynn Wilson

Board Member

Cadrenal Therapeutics, Inc. (CVKD)

Equibles does not estimate personal net worth.

Get an email with a short summary when Cadrenal Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get CVKD alerts

About Glynn Wilson

Glynn Wilson is recorded as Board Member at Cadrenal Therapeutics, Inc. (CVKD) since January 1, 2023. The newest filing on record that lists Glynn Wilson as Board Member at Cadrenal Therapeutics, Inc. (CVKD) is dated August 3, 2026. Cadrenal Therapeutics, Inc. reported in an 8-K filed June 29, 2026 that Glynn Wilson resigned as Class I director, effective June 29, 2026. Cadrenal Therapeutics, Inc. reported in an 8-K filed June 29, 2026 that Glynn Wilson was appointed Class III director, effective June 29, 2026. Cadrenal Therapeutics, Inc. reported in an 8-K filed January 25, 2023 that Glynn Wilson was appointed Class I director, effective January 19, 2023. Cadrenal Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cadrenal Therapeutics, Inc. includes John P. Sharp (CFO), Matthew K. Szot (CFO), Quang X. Pham (CFO, Chief Accounting Officer and Board Member) and 7 others.

“on June 29, 2026, Dr. Glynn Wilson resigned as a Class I director.”
Cadrenal Therapeutics, Inc. Form 8-K, filed June 29, 2026 · Read the filing
“The Board appointed him as a Class III director, effective immediately, to serve until the Corporation's 2028 annual meeting of stockholders, or until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.”
Cadrenal Therapeutics, Inc. Form 8-K, filed June 29, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at Cadrenal Therapeutics, Inc.

Recent activity